Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Replacing carbohydrates with monounsaturated fatty acids does not reduce blood pressure

13 Sep 2018

Substituting diets high in carbohydrates with those high in monounsaturated fatty acids (MUFAs) in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.

Researchers conducted a systematic review of randomized controlled trials evaluating the effect of a >3-week intervention of high-MUFA diets in isocaloric substitution for high-carbohydrate diets on systolic blood pressure (SBP) and diastolic blood pressure (DBP). A total of 14 trials representing 980 participants were included in the meta-analysis.

Pooled data, performed using the generic-inverse variance method, revealed that the high-MUFA diets in isocaloric substitution for high-carbohydrate diets did not result in a greater reduction in blood pressure (SBP: mean difference [MD], −0.08 mm Hg; 95 percent CI, −1.01 to 0.84; p=0.86; DBP: MD, 0.01 mm Hg; −0.73 to 0.75; p=0.98).

Dose-response analysis showed neither linear nor nonlinear associations between increasing dose of MUFA substitution for carbohydrates and blood pressure outcomes.

Visual inspection of funnel plots revealed no evidence of a publication bias. This was confirmed by Egger’s and Begg’s tests, which showed no significant small-study effects for either SBP or DBP. The overall quality of the evidence was assessed as moderate.

According to researchers, the analysis may be considered surprising, given that current dietary cardiovascular disease recommendations indicate a 1-unit reduction in SBP in adults with BP ranging 120–159/80–95 mm Hg after replacing 10 percent of energy intake from carbohydrates with MUFA.

Researchers recommend that future meta-analyses consider adopting the individual participant data approach. Additional high-quality substitution trials focusing on carbohydrate quality and considering higher MUFA (%E) target are also needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.